Chad Cooper, MD
Gastroenterology · Casper, WYNPI 1770876229
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.5%), grants and gifts — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Cook Medical LLC at 43.5% of the total. Reporting peaked in 2019 at $2,585 and has fallen 88.9% since, to $286 in 2025.
Across 157 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Medical LLC$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$568
- Gilead$320
- Olympus America Inc.$237
- Sanofi$146
- plus $557 from 13 others
What the payments were for
- Grants$2,26344%
- Food & beverage$2,88355%
- Gifts$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Medical LLC | 5 | $2,263 |
| AbbVie(2 entities) | 66 | $1,108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $568 |
| Gilead | 19 | $320 |
| Olympus America Inc. | 10 | $237 |
| Sanofi | 6 | $146 |
| Regeneron Healthcare Solutions, Inc. | 5 | $140 |
| Johnson & Johnson | 7 | $104 |
| Braintree Laboratories, Inc. | 1 | $53 |
| Pfizer | 3 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $47 |
| Mauna Kea Technologies, Inc. | 2 | $33 |
| UCB, Inc. | 1 | $25 |
| QOL Medical, LLC | 2 | $23 |
| Ambu Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $12 |
How this compares
Too few gastroenterology providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 20 | $609,645 |
| CreonLipase/Protease/Amylase | 71 | $107,995 |
| LinzessLinaclotide | 40 | $42,611 |
| Pantoprazole Sodium | 1,026 | $15,795 |
| Mesalamine | 16 | $12,050 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 22 | $3,592 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 43 | $2,838 |
| Omeprazole | 180 | $2,668 |
| Ursodiol | 32 | $2,399 |
| Balsalazide Disodium | 19 | $2,343 |
| Budesonide DrBudesonide | 28 | $2,123 |
| Sucralfate | 150 | $1,897 |
| Esomeprazole Magnesium | 17 | $1,564 |
| PrevaliteCholestyramine | 18 | $1,460 |
| Famotidine | 50 | $1,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $104 | $609,64520 claims |
| AbbVieCreon, Linzess | $1,108 | $150,606111 claims |
| Braintree Laboratories, Inc.Sutab | $53 | $3,59222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gastroenterology providers in Wyomingon file to place this against a meaningful peer group, so we don't.
Other gastroenterology in Casper
- Raoul JoubranCasper$5K
- Phillip KrmpotichCasper$5K
- Jeffrey CloudCasper$3K
- William ShearCasper$3K
- Kent KatzCasper$2K
- Luis ArmstrongCasper$2K
- Jamie SkroveCheyenne$5K
- Scott McRaeCheyenne$2K
- Charles KuckelCheyenne$440
- Kenneth KranzCheyenne$355
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.